PDF(Pubmed)
Abstract：
Tamoxifen, a selective estrogen receptor modulator (SERM), is a hormone therapy used for the treatment of estrogen receptor (ER)-positive breast cancer. We report the case of a 29-year-old premenopausal lady with a history of infertility treatments who was diagnosed with ER-positive infiltrating ductal carcinoma (IDC) of the breast. Following a modified radical mastectomy (MRM) and adjuvant systemic chemotherapy, tamoxifen was recommended as part of her adjuvant hormonal therapy. After over three years of tamoxifen use, the patient complained of gradual blurring of vision in both eyes. Ophthalmological examinations indicated bilateral maculopathy, a rare but alarming ocular side effect attributed to tamoxifen use. This case report emphasizes the significance of ophthalmic tests in patients on tamoxifen therapy to monitor any potential ocular side effects. While tamoxifen has shown remarkable benefits in the adjuvant treatment of ER-positive breast cancer, including lowering the chance of recurrence and increasing survival rates, clinicians must be acquainted with rare but potential vision-threatening consequences such as tamoxifen-induced maculopathy. Early detection and timely management are critical in reducing the risk of vision loss in patients receiving tamoxifen for breast cancer.
摘要：
他莫昔芬,选择性雌激素受体调节剂（SERM），是一种用于治疗雌激素受体（ER）阳性乳腺癌的激素疗法。我们报告了一名29岁的绝经前女士，有不孕症治疗史，被诊断患有ER阳性的乳腺浸润性导管癌（IDC）。在改良根治术（MRM）和辅助全身化疗后，他莫昔芬被推荐作为她的辅助激素治疗的一部分.使用他莫昔芬三年多之后,患者主诉双眼视力逐渐模糊.眼科检查提示双侧黄斑病变，一种罕见但令人震惊的眼部副作用归因于他莫昔芬的使用。此病例报告强调了他莫昔芬治疗患者的眼科检查对监测任何潜在的眼部副作用的重要性。虽然他莫昔芬在ER阳性乳腺癌的辅助治疗中显示出显著的益处，包括降低复发机会和提高生存率，临床医生必须了解罕见但潜在的视力威胁后果,如他莫昔芬诱发的黄斑病变.早期发现和及时管理对于降低接受他莫昔芬治疗的乳腺癌患者视力丧失的风险至关重要。
